News

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...
After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...
When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...
The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...
FuturHealth, a leader in personalized weight-loss solutions, today announced the appointment of Keith Koch as Executive Vice President of Growth Product & Experience Design. Koch, a veteran in digital ...